Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 636-643

  Blay, J Y ^a   Chauvin, F ^a   Le Cesne, A ^a   Anglaret, B ^a   Bouhour, D ^a   Lasset, C ^a   Freyer, G ^a   Philip, T ^a   Biron, P ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; FEVER; HIGH RISK POPULATION; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030058847     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.636     Document Type: Article

References (25)

1. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
2. Bodey G: Infection in cancer patients: A continuing association. Am J Med 8:11-26, 1986 (suppl 1A)
3. Klastersky J: Febrile neutropenia. Curr Opin Oncol 5:625-632, 1993
4. Pizzo PA, Meyers J, Freifeld AG, et al: Infection in the cancer patient, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer. Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 2292-2337
5. The International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 137:14-29, 1978
6. Pizzo PA, Hathorn JW, Hiemenz, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558, 1987
7. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
8. Hughes WT, Armstrong D, Bodey GP, et al: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381-396, 1990
9. Coiffier B, Gisselbrecht C, Herbrecht R, et al: LNH-84 regimen a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
10. Elias A, Ryan L, Sulkes A, et al: Response to Mesna, Doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7:1208-1216, 1989
11. Miser JS, Kinsella TJ, Triche TJ, et al: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987
12. Velasquez W, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 72:117-122, 1988
13. Nichols C, Williams S, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
14. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracile chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
15. The American Society of Clinical Oncology: American Society of Clinical Oncology recommandations for the use of hematopoietic colony stimulating factors: Evidence based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
16. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164-170, 1991
17. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. N Engl J Med 324:1773-1778, 1991
18. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
19. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
20. Gisselbrecht C, Prentice HG, Bacigalupo A, et al: Placebo controlled phase III trial of leniograstim in bone marrow transplantation. Lancet 343:696-700, 1994
21. Somers DM: A new asymmetric measure of association for ordinal variables. Am Soc Rev 27:799-811, 1962
22. Levine A: AIDS related lymphoma: Clinical aspects, in Broder S, Merigan TC, Bolognesi D (eds): Textbook of AIDS Medecine. William & Wilkins, Baltimore, MD, 1994, pp 465-472
23. Metcalf D: Hematopoietic regulators: Redundancy or subtelty? Blood 82:3515-3523, 1993
24. Chabner B: Anticancer drugs, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer. Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott 1993:325-417, 1993
25. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1994